In this update we are covering the news stories from December 2023, keeping you informed whether you are managing your own diabetes or doing so as a carer.
ARTHRITIS DRUG OFFERS HOPE FOR T1D
WALKING FASTER IMPROVES GLUCOSE LEVELS
NEW ENZYME DISCOVERY OFFERS HOPE FOR TYPE 1
Read more in the Mirror, click here.
WARNING FOR TYPE 1s USING FITNESS VIDEO GAMES
A Study carried out by Staffordshire University with Federal University of Vale do Sao Francisco has warned that type 1s need to exercise caution when using 'exergames'.
The Study analysed data from participants either running or playing the Kinect Adventures! video game. They found that it was difficult to measure intensity in the same way as real physical activity and noted that users were less aware of the effort they were using when participating virtually.
BROWN SEAWEED GOOD FOR T2D
An analysis carried out at Seoul National University of Science and Technology has shown that consumption of brown seaweed could be beneficial to persons with type 2 diabetes.
The researchers deduced from data looking at 23 previous studies, that consuming seaweed could prevent type 2 developing and also help to stabilise glucose levels in those with the condition. At least 1000 mg/day of seaweed or seaweed extract was needed to have a lowering effect on HbA1c.
Read more here.
DEXCOM G7 & TANDEM GETS FDA CLEARANCE TO LOOP
Following approval by the FDA in the USA, Tandem Diabetes Care’s t:slim X2 insulin pump is now able to connect with the Dexcom G7 CGM as an automated insulin delivery system using Tandem's Control-IQ algorithm.
This is set to clear the way for use soon in the UK and Europe, subject to approval & costs. Read more here.
iLET BIONICS PANCREAS LINKS TO DEXCOM G7 CGM
Beta Bionics have also announced that it has also partnered with Dexcom to enable an automated insulin delivery system using the G7 CGM, Beta Bionics’ insulin pump and dosing software, dubbed the iLet Bionic Pancreas.
Read more here.
MEDTRONIC PULLS OUT OF EOFLOW DEAL
Medtronic has pulled out of a $738 million deal to take over the South Korean company EOFlow, who manufacture an insulin patch-pump similar in design to Omnipod.
In October, Insulet (owner of the Omnipod brand) won a preliminary injunction in the USA against EOFlow, in relation to breaches of its patents. Insulet have also won similar legal cases brought in France and Germany.
Read more here.
That's it, you're up-to-date!
If you have any comments please send these by email to email@example.com
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyrightLove My Libre Ltd.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website www.lovemylibre.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses the FreeStyle Libre 2 which is provided on NHS prescription.